ArticleInternational journal of nanomedicine2026
ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium's anticancer properties. Methods: FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models. Results: Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity. Conclusion: This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.